drugset
drugset / Trial / NCT04410081

A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants

NCT04410081 ↗

Phase 1 Completed 8 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to characterize the absorption, metabolic pathways of lazertinib, and the excretion of the parent lazertinib and its metabolites, after a single oral dose of 14C-lazertinib in healthy adult male participants.

Timeline

Start
2020-07-14
Primary completion
2021-03-02
Completion
2021-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lazertinib Small molecule — Oral

Indications

No indication recorded.